Assessing the efficacy and safety of dual targeted therapy in patients with advanced or metastatic NSCLC harboring EGFRm+ and MET+ alterations

Overview

Targeted therapies such as osimertinib have brought significant benefits to patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. However, over time, some patients may develop resistance due to MET gene amplification or overexpression. This multicenter, multinational study was conducted to evaluate the efficacy of combining osimertinib with a MET inhibitor in order to simultaneously block both signaling pathways, with the expectation of improving disease control and prolonging survival for patients.

Inclusion Criteria

Participants aged ≥18 years
Diagnosed with advanced or metastatic NSCLC with EGFRm+ and MET+ alterations
Disease progression after treatment with osimertinib

Exclusion Criteria

Prior treatment with other third-generation EGFR-TKIs (besides osimertinib) or MET inhibitors
Significant cardiovascular or gastrointestinal disease affecting the ability to tolerate study drugs
Ongoing infection or severe systemic illness that could affect safety during participation

PI

MSc, MD Quách Thanh Dung – Oncology Center, Vinmec Times City Internation Hospital

Contact